Aevitas Therapeutics, a Fortress Biotech (FBIO) subsidiary company, and 4D Molecular Therapeutics (FDMT), announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H asset for the treatment of complement-mediated diseases. Under the terms of the agreement, 4DMT will make cash payments to Aevitas totaling up to ~$140 million in potential late-stage development, regulatory and sales milestones. A range of single-digit royalties on net sales are also payable. The aforementioned payments are payable solely to Aevitas, and 4DMT will be responsible for license payment obligations to University of Pennsylvania, where the sCFH technology was co-invented and co-developed by Dr. Wenchao Song, a Professor of Pharmacology at the Perelman School of Medicine. Aevitas’ transgene encoding sCFH, a shortened and optimized form of a natural inhibitor of the inflammatory complement pathway, will be combined with 4DMT’s proprietary retinotropic R100 vector to form product candidate 4D-175 for treatment of GA secondary to age-related macular degeneration.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FBIO:
- Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
- Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
- Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial